ReNeuron shares slump as company abandons retinitis pigmentosa program

19 January 2022

UK-based stem cell and exosomes technologies company ReNeuron Group (AIM: RENE) lost 44% of its stock market value on Tuesday.

The company had just announced a strategic update following a review of the latest data from the hRPC (human retinal progenitor cells) Phase IIa clinical trial for retinitis pigmentosa (RP) and an assessment of the commercial potential for its exosome technology.

"We cannot justify further substantial investment in the RP program"Although there have been no serious adverse events (SAEs) attributed to the drug itself, experience in treating the subjects at the two million cell dose has shown that the surgical procedure required to deliver this higher dose has led to more surgical complications compared to that seen with the one million cell dose.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK